MX2009010556A - Formas de dosificacion modificada de tacrolimus. - Google Patents
Formas de dosificacion modificada de tacrolimus.Info
- Publication number
- MX2009010556A MX2009010556A MX2009010556A MX2009010556A MX2009010556A MX 2009010556 A MX2009010556 A MX 2009010556A MX 2009010556 A MX2009010556 A MX 2009010556A MX 2009010556 A MX2009010556 A MX 2009010556A MX 2009010556 A MX2009010556 A MX 2009010556A
- Authority
- MX
- Mexico
- Prior art keywords
- tacrolimus
- amount
- hours
- released
- dosage forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Abstract
La presente invención provee una forma de dosificación de liberación modificada de tacrolimus que libera dos o más cantidades de tacrolimus tras la administración oral, en donde la primera cantidad de tacrolimus es liberada de la unidad de dosificación de liberación inmediata sustancialmente inmediatamente dentro de 0 a 2 horas, seguida de un intervalo de tiempo que varia de aproximadamente 1 a 10 horas durante el cual sustancialmente ninguna cantidad de tacrolimus es liberada de la forma de dosificación, después de lo cual una segunda cantidad de tacrolimus es liberada, en donde dicha segunda cantidad es liberada de la unidad de dosificación de liberación retardada inmediatamente, por ejemplo, dentro de 0 a 2 horas, o durante un período que varía de aproximadamente 2 a 12 horas de su liberación inicial de la unidad de dosificación de liberación retardada; la forma de dosificación puede comprender además una cantidad adicional de tacrolimus para proveer pulso adicional de tacrolimus; las formas de dosificación de tacrolimus exhiben biodisponibilidad mejorada y flujo o fluctuación reducido sobre la composición existente de tacrolimus; se describe también un método para preparar las formas de dosificación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN583MU2007 | 2007-03-29 | ||
PCT/IN2008/000179 WO2009022354A2 (en) | 2007-03-29 | 2008-03-25 | Modified dosage forms of tacrolimus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009010556A true MX2009010556A (es) | 2009-10-22 |
Family
ID=39642954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010556A MX2009010556A (es) | 2007-03-29 | 2008-03-25 | Formas de dosificacion modificada de tacrolimus. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100086592A1 (es) |
EP (1) | EP1974722A3 (es) |
JP (1) | JP2010522742A (es) |
KR (1) | KR20100014629A (es) |
CN (1) | CN101652141A (es) |
AU (1) | AU2008288105A1 (es) |
BR (1) | BRPI0809563A2 (es) |
CA (1) | CA2680680A1 (es) |
CL (1) | CL2008000914A1 (es) |
EA (1) | EA200970897A1 (es) |
IL (1) | IL201008A0 (es) |
MX (1) | MX2009010556A (es) |
NZ (1) | NZ579811A (es) |
UA (1) | UA93148C2 (es) |
WO (1) | WO2009022354A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2167033T (lt) * | 2007-05-30 | 2017-08-10 | Veloxis Pharmaceuticals A/S | Kartą per dieną vartojama geriamoji vaisto forma, apimanti takrolimą |
EP2309999A1 (en) * | 2008-06-26 | 2011-04-20 | McNeil-PPC, Inc. | Coated particles containing pharmaceutically active agents |
KR101174183B1 (ko) | 2008-11-28 | 2012-08-16 | 주식회사 삼양바이오팜 | 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법 |
SG174658A1 (en) | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
KR101873075B1 (ko) * | 2010-08-18 | 2018-06-29 | 에보니크 룀 게엠베하 | 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제 |
KR101243938B1 (ko) | 2010-10-19 | 2013-03-19 | 이희엽 | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 |
BR112013028755A2 (pt) | 2011-05-10 | 2017-01-31 | Theravida Inc | combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa |
DE102011053068A1 (de) * | 2011-08-29 | 2013-02-28 | Hennig Arzneimittel Gmbh & Co. Kg | Darreichungsform mit stabilisierten Wirkstoffpartikeln |
KR20130028824A (ko) * | 2011-09-09 | 2013-03-20 | 주식회사 삼양바이오팜 | 타크로리무스를 포함하는 고체 분산체 및 이의 제조방법 |
MX355662B (es) | 2012-08-27 | 2018-04-25 | Evonik Roehm Gmbh | Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influencia de etanol. |
WO2016025533A2 (en) * | 2014-08-11 | 2016-02-18 | Whitehead Institute For Biomedical Research | Compositions and methods for treating synucleinopathies |
CN104473907A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种他克莫司的口服缓释制剂 |
US10022328B2 (en) | 2015-02-20 | 2018-07-17 | Cytec Industries Inc. | Dialkyl sulfosuccinate compositions, method of making, and method of use |
JP6841834B2 (ja) | 2016-01-20 | 2021-03-10 | テラヴィダ, インコーポレイテッドTheraVida, Inc. | 多汗症の処置のための方法および組成物 |
JP2021529765A (ja) | 2018-06-29 | 2021-11-04 | インサイト・コーポレイションIncyte Corporation | Axl/mer阻害剤の製剤 |
CA3063417C (en) * | 2018-12-04 | 2023-01-03 | Leon-Nanodrugs Gmbh | Nanoparticles comprising tacrolimus |
GR1009790B (el) * | 2019-03-20 | 2020-08-03 | Φαρματεν Α.Β.Ε.Ε. | Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους |
US10752642B1 (en) | 2019-04-30 | 2020-08-25 | George Mason University | Macrocyclic lactones |
CN112569187B (zh) * | 2019-09-27 | 2022-04-12 | 武汉科福新药有限责任公司 | 一种他克莫司纳米眼用乳及其制备方法 |
US11666560B2 (en) | 2020-09-24 | 2023-06-06 | George Mason University | Anti-fibrotic agent |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200002771T2 (tr) * | 1998-03-26 | 2001-02-21 | Fujisawa Pharmaceutical Co.,Ltd. | Devamlı salımı olan preparatlar |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AU2004267910B2 (en) * | 2003-08-29 | 2011-01-06 | Veloxis Pharmaceuticals, Inc. | Solid dispersions comprising tacrolimus |
JP4903568B2 (ja) | 2003-08-29 | 2012-03-28 | ベロクシス ファーマシューティカルズ エー/エス | タクロリムスを含む固体分散体 |
DE10353196A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
US7470435B2 (en) * | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
-
2008
- 2008-03-25 MX MX2009010556A patent/MX2009010556A/es not_active Application Discontinuation
- 2008-03-25 WO PCT/IN2008/000179 patent/WO2009022354A2/en active Application Filing
- 2008-03-25 AU AU2008288105A patent/AU2008288105A1/en not_active Abandoned
- 2008-03-25 BR BRPI0809563-9A2A patent/BRPI0809563A2/pt not_active IP Right Cessation
- 2008-03-25 JP JP2010500442A patent/JP2010522742A/ja not_active Withdrawn
- 2008-03-25 CA CA002680680A patent/CA2680680A1/en not_active Abandoned
- 2008-03-25 EA EA200970897A patent/EA200970897A1/ru unknown
- 2008-03-25 KR KR1020097020203A patent/KR20100014629A/ko not_active Application Discontinuation
- 2008-03-25 NZ NZ579811A patent/NZ579811A/en not_active IP Right Cessation
- 2008-03-25 US US12/530,011 patent/US20100086592A1/en not_active Abandoned
- 2008-03-25 UA UAA200909959A patent/UA93148C2/ru unknown
- 2008-03-25 CN CN200880010774A patent/CN101652141A/zh active Pending
- 2008-03-28 CL CL200800914A patent/CL2008000914A1/es unknown
- 2008-03-28 EP EP08006027A patent/EP1974722A3/en not_active Withdrawn
-
2009
- 2009-09-17 IL IL201008A patent/IL201008A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2008000914A1 (es) | 2008-07-18 |
JP2010522742A (ja) | 2010-07-08 |
IL201008A0 (en) | 2010-05-17 |
CN101652141A (zh) | 2010-02-17 |
WO2009022354A2 (en) | 2009-02-19 |
BRPI0809563A2 (pt) | 2014-09-16 |
EP1974722A3 (en) | 2009-03-04 |
UA93148C2 (ru) | 2011-01-10 |
NZ579811A (en) | 2012-02-24 |
EP1974722A2 (en) | 2008-10-01 |
EA200970897A1 (ru) | 2010-04-30 |
WO2009022354A3 (en) | 2009-04-09 |
US20100086592A1 (en) | 2010-04-08 |
CA2680680A1 (en) | 2009-02-19 |
AU2008288105A1 (en) | 2009-02-19 |
KR20100014629A (ko) | 2010-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA93148C2 (ru) | Дозированная форма тароликмуса модифицированного высвобождения | |
GEP20146166B (en) | Pharmaceutical composition | |
MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
WO2007090882A3 (en) | Pharmaceutical extended release compositions comprising pramipexole | |
MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
TN2012000248A1 (en) | Novel spiropiperidine compounds | |
TW200730200A (en) | Method for the preparation of a wet granulated drug product | |
TW200745149A (en) | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
MY175800A (en) | Combination treatment of cancer | |
MX2011012122A (es) | Derivados de tiofeno. | |
HK1136828A1 (en) | Spirocyclic cyclohexane derivatives | |
GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
WO2013012485A3 (en) | Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
EA201171271A1 (ru) | Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида | |
WO2012052169A3 (de) | Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten | |
WO2013128379A3 (en) | Crystalline polymorphic forms of linagliptin | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
TW200833371A (en) | Process for solid formulations | |
MA34580B1 (fr) | Valsartan hautement cristallin | |
WO2012151464A3 (en) | Use of radiographic contrast agents for detecting dental caries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |